留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植术后糖尿病的最新进展

肖正楠 李俊辉 蒋捷 周赵沁 张宇 郭郴 王锰 明英姿

肖正楠, 李俊辉, 蒋捷, 等. 肝移植术后糖尿病的最新进展[J]. 器官移植, 2021, 12(5): 630-636. doi: 10.3969/j.issn.1674-7445.2021.05.020
引用本文: 肖正楠, 李俊辉, 蒋捷, 等. 肝移植术后糖尿病的最新进展[J]. 器官移植, 2021, 12(5): 630-636. doi: 10.3969/j.issn.1674-7445.2021.05.020
Xiao Zhengnan, Li Junhui, Jiang Jie, et al. Recent progress on diabetes mellitus after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 630-636. doi: 10.3969/j.issn.1674-7445.2021.05.020
Citation: Xiao Zhengnan, Li Junhui, Jiang Jie, et al. Recent progress on diabetes mellitus after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 630-636. doi: 10.3969/j.issn.1674-7445.2021.05.020

肝移植术后糖尿病的最新进展

doi: 10.3969/j.issn.1674-7445.2021.05.020
基金项目: 

国家自然科学基金 81771722

详细信息
    作者简介:

    肖正楠,男,1996年生,硕士研究生,研究方向为肝移植,Email:xiaozn1996@163.com

    通讯作者:

    明英姿,女,1970年生,博士,教授,主任医师,研究方向为肝、肾移植, E-mail: myz_china@aliyun.com

  • 中图分类号: R617, R587.1

Recent progress on diabetes mellitus after liver transplantation

More Information
  • 摘要: 糖尿病是肝移植术后最常见的并发症之一,肝移植术后并发糖尿病的受者生存率及移植物长期存活率明显低于无糖尿病的肝移植受者。近年来,随着肝移植在中国迅速发展,肝移植术后糖尿病也引发了高度关注。尽管过去20余年对于移植后糖尿病(PTDM)的研究从未停歇,但仍有许多问题有待进一步研究解决。本文旨在总结肝移植术后糖尿病的最新研究进展,包括PTDM的定义与诊断标准,肝移植术后糖尿病的危险因素、预防及治疗等,以期加深对于肝移植术后糖尿病的认识和理解,并进行有效预防和治疗,从而提高肝移植受者长期存活率及生活质量。

     

  • [1] SCHNITZLER MA, SKEANS MA, AXELROD DA, et al. OPTN/SRTR 2016 annual data report: economics[J]. Am J Transplant, 2018, 18(Suppl 1): 464-503. DOI: 10.1111/ajt.14564.
    [2] 杨墨丹, 鲁迪, 陈俊丽, 等. 大数据时代背景下的中国肝移植质量提升[J/CD]. 实用器官移植电子杂志, 2020, 8(2): 93-95. DOI: 10.3969/j.issn.2095-5332.2020.02.004.

    YANG MD, LU D, CHEN JL, et al. Liver transplantation quality improvement in China in the era of big data[J/CD]. Pract J Organ Transplant (ElectrVers), 2020, 8(2): 93-95. DOI: 10.3969/j.issn.2095-5332.2020.02.004.
    [3] LING Q, XU X, WANG B, et al. The origin of new-onset diabetes after liver transplantation: liver, islets, or gut?[J]. Transplantation, 2016, 100(4): 808-813. DOI: 10.1097/TP.0000000000001111.
    [4] LING Q, XU X, XIE H, et al. New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry[J]. Liver Int, 2016, 36(5): 705-712. DOI: 10.1111/liv.13042.
    [5] ROCCARO GA, GOLDBERG DS, HWANG WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Transplant, 2018, 18(1): 207-215. DOI: 10.1111/ajt.14401.
    [6] RAMOS-PROL A, HERVÁS-MARÍN D, GARCÍA-CASTELL A, et al. Outcomes in patients with diabetes 10 years after liver transplantation[J]. J Diabetes, 2017, 9(11): 1033-1039. DOI: 10.1111/1753-0407.12520.
    [7] LIEBER SR, LEE RA, JIANG Y, et al. The impact of post-transplant diabetes mellitus on liver transplant outcomes[J]. Clin Transplant, 2019, 33(6): e13554. DOI: 10.1111/ctr.13554.
    [8] DAVIDSON J, WILKINSON A, DANTAL J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003, 75(10 Suppl): SS3-SS24. DOI: 10.1097/01.TP.0000069952.49242.3E.
    [9] SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
    [10] CHOWDHURY TA. Post-transplant diabetes mellitus[J]. Clin Med (Lond), 2019, 19(5): 392-395. DOI: 10.7861/clinmed.2019-0195.
    [11] American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2014, 37(Suppl 1): S81-S90. DOI: 10.2337/dc14-S081.
    [12] SHIVASWAMY V, BOERNER B, LARSEN J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
    [13] ZHANG T, LIU Y, HU Y, et al. Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population[J]. Gene, 2017, 627: 428-433. DOI: 10.1016/j.gene.2017.06.060.
    [14] GRANCINI V, RESI V, PALMIERI E, et al. Management of diabetes mellitus in patients undergoing liver transplantation[J]. Pharmacol Res, 2019, 141: 556-573. DOI: 10.1016/j.phrs.2019.01.042.
    [15] PERACHA J, NATH J, READY A, et al. Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients[J]. Transpl Int, 2016, 29(6): 727-739. DOI: 10.1111/tri.12782.
    [16] TAN HL, LIM KB, IYER SG, et al. Metabolic syndrome after a liver transplantation in an Asian population[J]. HPB (Oxford), 2015, 17(8): 713-722. DOI: 10.1111/hpb.12435.
    [17] VON DÜRING ME, JENSSEN T, BOLLERSLEV J, et al. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation[J]. Transpl Int, 2015, 28(10): 1162-1171. DOI: 10.1111/tri.12606.
    [18] ROCCARO GA, MITRANI R, HWANG WT, et al. Sustained virological response is associated with a decreased risk of posttransplant diabetes mellitus in liver transplant recipients with hepatitis C-related liver disease[J]. Liver Transpl, 2018, 24(12): 1665-1672. DOI: 10.1002/lt.25351.
    [19] RUSSO FP, ZANETTO A, GAMBATO M, et al. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance[J]. J Viral Hepat, 2020, 27(2): 188-194. DOI: 10.1111/jvh.13215.
    [20] LI DW, LU TF, HUA XW, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a Meta-analysis[J]. World J Gastroenterol, 2015, 21(20): 6329-6340. DOI: 10.3748/wjg.v21.i20.6329.
    [21] LIANG J, LV C, CHEN M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5): 370-378. DOI: 10.1111/1753-0407.12853.
    [22] ORSI E, GRANCINI V, MENINI S, et al. Hepatogenous diabetes: is it time to separate it from type 2 diabetes?[J]. Liver Int, 2017, 37(7): 950-962. DOI: 10.1111/liv.13337.
    [23] SEPEHRI Z, KIANI Z, AFSHARI M, et al. Inflammasomes and type 2 diabetes: an updated systematic review[J]. Immunol Lett, 2017, 192: 97-103. DOI: 10.1016/j.imlet.2017.10.010.
    [24] IONUT V, CASTRO AV, WOOLCOTT OO, et al. Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia[J]. Am J Physiol Endocrinol Metab, 2014, 307(8): E644-E652. DOI: 10.1152/ajpendo.00244.2014.
    [25] MÜLLER MM, SCHWAIGER E, KURNIKOWSKI A, et al. Glucose metabolism after kidney transplantation: insulin release and sensitivity with tacrolimus- versus belatacept-based immunosuppression[J]. Am J Kidney Dis, 2021, 77(3): 462-464. DOI: 10.1053/j.ajkd.2020.07.016.
    [26] UME AC, WENEGIEME TY, WILLIAMS CR. Calcineurin inhibitors: a double-edged sword[J]. Am J Physiol Renal Physiol, 2021, 320(3): F336-F341. DOI: 10.1152/ajprenal.00262.2020.
    [27] TRIÑANES J, RODRIGUEZ-RODRIGUEZ AE, BRITO-CASILLAS Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells[J]. Am J Transplant, 2017, 17(11): 2829-2840. DOI: 10.1111/ajt.14323.
    [28] TORRES A, HERNÁNDEZ D, MORESO F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus[J]. Kidney Int Rep, 2018, 3(6): 1304-1315. DOI: 10.1016/j.ekir.2018.07.009.
    [29] CHEVALLIER E, JOUVE T, ROSTAING L, et al. pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression[J]. Expert Rev Clin Pharmacol, 2021, 14(1): 55-66. DOI: 10.1080/17512433.2021.1851596.
    [30] BLAGOSKLONNY MV. Fasting and rapamycin: diabetes versus benevolent glucose intolerance[J]. Cell Death Dis, 2019, 10(8): 607. DOI: 10.1038/s41419-019-1822-8.
    [31] BHAT V, TAZARI M, WATT KD, et al. New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: a machine learning approach[J]. Mayo Clin Proc, 2018, 93(12): 1794-1802. DOI: 10.1016/j.mayocp.2018.06.020.
    [32] JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
    [33] LINDER KE, BAKER WL, ROCHON C, et al. Evaluation of posttransplantation diabetes mellitus after liver transplantation: assessment of insulin administration as a risk factor[J]. Ann Pharmacother, 2016, 50(5): 369-375. DOI: 10.1177/1060028015627662.
    [34] LI Z, SUN F, HU Z, et al. New-onset diabetes mellitus in liver transplant recipients with hepatitis C: analysis of the national database[J]. Transplant Proc, 2016, 48(1): 138-144. DOI: 10.1016/j.transproceed.2015.11.010.
    [35] XUE M, LV C, CHEN X, et al. Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation[J]. J Diabetes Investig, 2017, 8(2): 181-187. DOI: 10.1111/jdi.12560.
    [36] HARTOG H, MAY CJ, CORBETT C, et al. Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury[J]. Liver Int, 2015, 35(6): 1739-1747. DOI: 10.1111/liv.12706.
    [37] 中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1): 1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for diagnosis and treatment of post transplantation diabetes mellitus in China (2019 edition)[J]. Organ Transplant, 2019, 10(1): 1-9. DOI: 10.3969/j.issn.1674-7445.2019.01.001.
    [38] SHIMADA H, UCHIDA J, NISHIDE S, et al. Comparison of glucose tolerance between kidney transplant recipients and healthy controls[J]. J Clin Med, 2019, 8(7): 920. DOI: 10.3390/jcm8070920.
    [39] HARE MJ, SHAW JE, ZIMMET PZ. Current controversies in the use of haemoglobin A1c[J]. J Intern Med, 2012, 271(3): 227-236. DOI: 10.1111/j.1365-2796.2012.02513.x.
    [40] WISSING KM, ABRAMOWICZ D, WEEKERS L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation[J]. Am J Transplant, 2018, 18(7): 1726-1734. DOI: 10.1111/ajt.14665.
    [41] CASTEDAL M, SKOGLUND C, AXELSON C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018, 53(6): 741-747. DOI: 10.1080/00365521.2018.1463390.
    [42] MORGAN RD, O'CALLAGHAN JM, KNIGHT SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and Meta-analysis[J]. Transplantation, 2012, 93(12): 1179-1788. DOI: 10.1097/TP.0b013e318257ad41.
    [43] HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
    [44] LARSEN JL. Potential risks of metformin in transplant patients[J]. Am J Transplant, 2012, 12(3): 795-796. DOI: 10.1111/j.1600-6143.2011.03921.x.
    [45] LO C, TOYAMA T, OSHIMA M, et al. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients[J]. Cochrane Database Syst Rev, 2020, 8: CD009966. DOI: 10.1002/14651858.CD009966.pub3.
    [46] HALDEN TA, EGELAND EJ, ÅSBERG A, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes[J]. Diabetes Care, 2016, 39(4): 617-624. DOI: 10.2337/dc15-2383.
    [47] ARODA VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials[J]. Diabetes Obes Metab, 2018, 20(Suppl 1): 22-33. DOI: 10.1111/dom.13162.
    [48] ALKINDI F, AL-OMARY HL, HUSSAIN Q, et al. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients[J]. Transplant Proc, 2020, 52(1): 175-178. DOI: 10.1016/j.transproceed.2019.11.007.
    [49] RAJASEKERAN H, KIM SJ, CARDELLA CJ, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series[J]. Diabetes Care, 2017, 40(7): e75-e76. DOI: 10.2337/dc17-0237.
    [50] JIN J, JIN L, LUO K, et al. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury[J]. Am J Transplant, 2017, 17(10): 2601-2616. DOI: 10.1111/ajt.14316.
    [51] ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and Meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
    [52] GAIFFE E, CREPIN T, BAMOULID J, et al. PRODIG (prevention of new onset diabetes after transplantation by a short term treatment of vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study[J]. Trials, 2019, 20(1): 375. DOI: 10.1186/s13063-019-3392-6.
    [53] LEE M, SHIN E, BAE J, et al. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression[J]. Sci Rep, 2020, 10(1): 19429. DOI: 10.1038/s41598-020-75288-y.
  • 加载中
图(1)
计量
  • 文章访问数:  546
  • HTML全文浏览量:  217
  • PDF下载量:  110
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-04-16
  • 网络出版日期:  2021-09-15
  • 刊出日期:  2021-09-15

目录

    /

    返回文章
    返回